Burrage Capital Management LLC - Q1 2020 holdings

$102 Million is the total value of Burrage Capital Management LLC's 31 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .

 Value Shares↓ Weighting
SLDB ExitSolid Biosciences Inc$0-80,487
-100.0%
-0.24%
ABMD ExitABIOMED Inc$0-10,138
-100.0%
-1.16%
DRNA ExitDicerna Pharmaceuticals Inc$0-104,047
-100.0%
-1.54%
USPH ExitUS Physical Therapy Inc$0-21,500
-100.0%
-1.65%
DCPH ExitDeciphera Pharmaceuticals Inc$0-59,818
-100.0%
-2.50%
ASND ExitAscendis Pharma A/Ssponsored adr$0-43,775
-100.0%
-4.08%
ARQL ExitArQule Inc$0-595,018
-100.0%
-7.96%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-05-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
EPIZYME INC COM7Q2 202115.9%
NeoGenomics Inc7Q2 20218.7%
OrthoPediatrics Corp7Q2 20217.3%
Y-MABS THERAPEUTICS INC COM7Q2 20214.3%
CRINETICS PHARMACEUTICALS INC COM7Q2 20215.6%
G1 THERAPEUTICS INC COM7Q2 20217.3%
PTC THERAPEUTICS INC COM6Q1 20218.0%
CYTOKINETICS INC COM NEW6Q2 20214.9%
TURNING PT THERAPEUTICS INC COM6Q2 20216.7%
APELLIS PHARMACEUTICALS INC COM6Q1 20213.5%

View Burrage Capital Management LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Burrage Capital Management LLC Q1 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Protalix BioTherapeutics, Inc.Sold outJuly 30, 202100.0%
IVERIC bio, Inc.February 14, 2020103.4%

View Burrage Capital Management LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2021-11-15
13F-HR2021-08-16
SC 13G/A2021-07-30
13F-HR2021-05-17
13F-HR2021-02-12
SC 13G2021-02-12
13F-HR2020-11-13
13F-HR2020-08-14
13F-HR2020-05-14
13F-HR2020-02-14

View Burrage Capital Management LLC's complete filings history.

Compare quarters

Export Burrage Capital Management LLC's holdings